AU2012232706B2 - Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators - Google Patents

Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators Download PDF

Info

Publication number
AU2012232706B2
AU2012232706B2 AU2012232706A AU2012232706A AU2012232706B2 AU 2012232706 B2 AU2012232706 B2 AU 2012232706B2 AU 2012232706 A AU2012232706 A AU 2012232706A AU 2012232706 A AU2012232706 A AU 2012232706A AU 2012232706 B2 AU2012232706 B2 AU 2012232706B2
Authority
AU
Australia
Prior art keywords
ethyl
methyl
oxazin
amino
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012232706A
Other languages
English (en)
Other versions
AU2012232706A1 (en
Inventor
Sarde Gangaram Ankush
Ganesh Navinchandra Gote
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Venkata P. Palle
Chetan Sanjay Pawar
Majid Bashir Sayyed
Manojkumar Ramprasad Shukla
Mahadeo Bhaskar Tryambake
Pachpute Dilip Vipul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Atlantis Holdings SA
Original Assignee
Lupin Atlantis Holdings SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings SA filed Critical Lupin Atlantis Holdings SA
Publication of AU2012232706A1 publication Critical patent/AU2012232706A1/en
Assigned to LUPIN ATLANTIS AOLDINGS SA reassignment LUPIN ATLANTIS AOLDINGS SA Request for Assignment Assignors: LUPIN LIMITED
Application granted granted Critical
Publication of AU2012232706B2 publication Critical patent/AU2012232706B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2012232706A 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators Ceased AU2012232706B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
IN367/KOL/2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (2)

Publication Number Publication Date
AU2012232706A1 AU2012232706A1 (en) 2013-09-26
AU2012232706B2 true AU2012232706B2 (en) 2016-12-15

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012232706A Ceased AU2012232706B2 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Country Status (16)

Country Link
US (1) US9464063B2 (enExample)
EP (1) EP2686306B1 (enExample)
JP (1) JP6033835B2 (enExample)
KR (1) KR20140051846A (enExample)
CN (1) CN103459377B (enExample)
AP (1) AP2013007153A0 (enExample)
AU (1) AU2012232706B2 (enExample)
BR (1) BR112013023914A2 (enExample)
CA (1) CA2829466A1 (enExample)
EA (1) EA024893B9 (enExample)
IL (1) IL228461A0 (enExample)
MX (1) MX2013010670A (enExample)
PH (1) PH12013501899A1 (enExample)
SG (1) SG193331A1 (enExample)
WO (2) WO2012127388A1 (enExample)
ZA (1) ZA201306837B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102041154B1 (ko) 2012-02-24 2019-11-07 루핀 리미티드 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
HK1211916A1 (en) * 2012-08-27 2016-06-03 Lupin Atlantis Holdings Sa Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
US9493396B2 (en) 2013-08-28 2016-11-15 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
AU2020415502A1 (en) 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
SI4090654T1 (sl) * 2020-01-17 2025-11-28 Lupin Ltd. Metode, postopki in intermediati za pripravo kromanskih spojin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
CA2527203C (en) 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
MX2009003981A (es) * 2006-10-26 2009-04-27 Amgen Inc Agentes moduladores del receptor de calcio.
WO2008059854A1 (en) * 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
CA2706076A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 ＣａＳＲアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1882684A1 (en) * 2005-05-19 2008-01-30 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof

Also Published As

Publication number Publication date
CN103459377A (zh) 2013-12-18
WO2012127388A1 (en) 2012-09-27
PH12013501899A1 (en) 2013-11-25
SG193331A1 (en) 2013-10-30
MX2013010670A (es) 2013-12-06
EP2686306A1 (en) 2014-01-22
JP2014510097A (ja) 2014-04-24
AU2012232706A1 (en) 2013-09-26
NZ616676A (en) 2015-09-25
US9464063B2 (en) 2016-10-11
EA201370205A1 (ru) 2014-01-30
KR20140051846A (ko) 2014-05-02
IL228461A0 (en) 2013-12-31
WO2012127385A1 (en) 2012-09-27
US20140018358A1 (en) 2014-01-16
BR112013023914A2 (pt) 2016-12-13
EA024893B1 (ru) 2016-10-31
EA024893B9 (ru) 2017-01-30
ZA201306837B (en) 2015-05-27
AP2013007153A0 (en) 2013-09-30
JP6033835B2 (ja) 2016-11-30
EP2686306B1 (en) 2017-01-04
CN103459377B (zh) 2016-09-07
CA2829466A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EP2686306B1 (en) Benzo[b][1,4]oxazin derivatives as calcium sensing receptor modulators
AU2012226375B2 (en) Substituted morpholines as modulators for the calcium sensing receptor
CA2864332C (en) Substituted chroman compounds as calcium sensing receptor modulators
JP2019522005A (ja) 芳香族アセチレンまたは芳香族エチレン系化合物、その中間体、製造方法、薬物組成物および使用
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2013136288A1 (en) Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
US9598371B2 (en) Arylalkylamine compounds as calcium sensing receptor modulators
NZ616676B2 (en) Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators
OA16592A (en) Benzo [B][1,4] oxazin derivatives as calcium sensing receptor modulators.
HK1192544B (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
HK1192544A (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
HK1205117B (en) Substituted chroman compounds as calcium sensing receptor modulators
OA17086A (en) Substituted chroman compounds as calcium sensing receptor modulators.

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LUPIN ATLANTIS AOLDINGS SA

Free format text: FORMER APPLICANT(S): LUPIN LIMITED

TH Corrigenda

Free format text: IN VOL 30 , NO 17 , PAGE(S) 2300 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2012 UNDER THE NAME LUPIN ATLANTIS AOLDCORRIGENDA INGS SA, APPLICATION NO. 2012232706, UNDER INID (71) CORRECT APPLICANT NAME TO LUPIN ATLANTIS HOLDINGS SA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired